Caprion

Finding proteins that hit the mark

News

Caprion Introduces CNS ProteoCartaTM—Customizable and Highly Multiplexed Assay for Studying Neurological Disease

Montreal, Canada – April 29, 2014 – Caprion announced today the launch of CNS
ProteoCarta™, a cerebrospinal fluid (CSF) proteomic panel for the study of CNS (Central
Nervous System) diseases at the Translational CNS Summit 2014 in Boston, Massachusetts.

Working in conjunction with The Foundation for the National Institutes of Health’s Biomarkers
Consortium as the selected discovery partner, Caprion developed CNS ProteoCarta™, an easily
customizable and highly multiplexed mass spectrometry based assay, useful in monitoring CNS
proteins associated with neurological disorders such as Alzheimer’s and Parkinson’s disease.
CNS ProteoCarta™ allows for the simultaneous detection and quantification of 142 proteins in
75uL of human CSF in a single, multiplexed Multiple Reaction Monitoring (MRM) assay.

“The CNS-specific nature of this large protein panel provides a great opportunity for
researchers to identify useful biomarkers,” said Daniel Chelsky, Ph.D., Chief Scientific Officer of
Caprion. “An important feature is the assay’s efficient and extensive adaptability, where by
over 100 disease-specific proteins may be added on a custom basis.”

CNS disorders bear an economic burden of more than $2 trillion in the US and EU, and are
growing in incidence faster than any other disease class. Neurological disorders inflict higher
treatment and productivity loss costs than diabetes, cardiovascular disease and cancer
combined.


Martin LeBlanc, President and CEO of Caprion, commented, “The CNS ProteoCarta proteomic
panel is another example of Caprion’s industry leadership in targeted proteomics, and the first
of several new multiplexed MRM assays targeting specific therapeutic and drug development
areas that Caprion intends to launch over the coming year in response to increasing demand
and high interest from our clients.”


About Caprion Inc.

Caprion is the leading provider of proteomics and immune monitoring services to the
pharmaceutical and biotechnology industry. Its immune monitoring business unit,
ImmuneCarta™, offers proprietary multiparametric flow cytometry for functional analyses of
innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta™,
offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative
and robust comparative measurement of proteins across large sets of biological samples for the
discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta™ to develop
its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With
research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing largescale
proteomics and immune monitoring services to over 50 major pharmaceutical and biotech
clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago
Growth Partners. For more information, please visit www.caprion.com.

About the Foundation for the NIH

Established by the United States Congress to support the mission of the NIH—improving health
through scientific discovery in the search for cures—the Foundation for the NIH is a leader in
identifying and addressing complex scientific and health issues. The Foundation is a non-profit,
501(c)(3) charitable organization that raises private-sector funds for a broad portfolio of unique
programs that complement and enhance NIH priorities and activities. For additional
information about the Foundation for the NIH, please visit www.fnih.org.

About the Biomarkers Consortium

The Biomarkers Consortium is a public-private biomedical research partnership managed by the
Foundation for the National Institutes of Health (FNIH) that endeavors to develop, validate,
and/or qualify biological markers (biomarkers) to speed the development of medicines and
therapies for detection, prevention, diagnosis and treatment of disease and improve patient
care. For additional information about the Biomarkers Consortium, please visit
www.biomarkersconsortium.org.

Media Contact
Carol Berry
Chief Business Officer, SVP
Caprion, Inc.
cberry@caprion.com or 514.360.3600

Back to news list

© 2017 Caprion